Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on March 11, 2008
JNCI Journal of the National Cancer Institute 2008 100(6):376-377; doi:10.1093/jnci/djn055
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/6/376    most recent
djn055v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wu, A.
Right arrow Articles by Ji, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, A.
Right arrow Articles by Ji, J.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

Adjuvant Chemotherapy for Gastric Cancer or Not: A Dilemma?

Aiwen Wu, Jiafu Ji

Affiliation of authors: Department of Gastrointestinal Surgery, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China

Correspondence to: Aiwen Wu, MD, Department of Gastrointestinal Surgery, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China 100036 (e-mail: wuaw@sina.com).

The first 10% of the full text of this article appears below.

In this issue of the Journal, Di Costanzo et al. (1) report the result of a randomized phase III trial of the Italian Oncology Group for Cancer Research. They conclude that despite very promising previous results in the setting of advanced gastric cancer (2), there are no positive effects of cisplatin, epirubicin, leucovorin, and 5-fluorouracil (PELF) as adjuvant chemotherapy on overall and disease-free survival of gastric cancer patients who have undergone complete surgical resection. In the trial, 258 patients were randomly assigned to chemotherapy or surgery alone over a 5-year period. Fifty-five percent of the patients underwent D2 or more extended nodal dissection, and the median number of lymph nodes harvested per patient was greater than 15. The study . . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC
Francesco Di Costanzo, Silvia Gasperoni, Luigi Manzione, Giancarlo Bisagni, Roberto Labianca, Stefano Bravi, Enrico Cortesi, Paolo Carlini, Raffaella Bracci, Silverio Tomao, Luca Messerini, Annarosa Arcangeli, Valter Torri, Domenico Bilancia, Irene Floriani, and Maurizio Tonato On behalf of Italian Oncology Group for Cancer Research
J Natl Cancer Inst 2008 100: 388-398. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2008 100: 375. [Extract] [Full Text] [PDF]